Helicobacter Pylori Diagnostics Market share, Size, trends and industry Analysis

 

Helicobacter Pylori Diagnostics

Helicobacter is a spiral-shaped gram-negative bacterium that causes ulcers in the stomach and duodenum by producing persistent inflammation and infection. H. pylori is identified in 50-80 percent of gastric ulcer patients and 90 percent of duodenal ulcer patients. Peptic ulcer disease is likely to develop in one out of every six people infected with H. pylori. Infected people have long-term asymptomatic problems, with over 70% of them experiencing minor symptoms including belching, bloating, nausea, vomiting, and stomach discomfort on a regular basis, whilst significant symptoms include abdominal pain, peptic ulcers, and foul breath. Invasive tests, which need stomach mucosa samples collected by endoscopy and utilised for biopsy, or non-invasive testing, which require blood or stool samples, can be used to identify Helicobacter infection.

The global Helicobacter Pylori Diagnostics Market size was valued at US$ 437.3 million in 2017 and is expected to witness a CAGR of 7.1% over the forecast period (2018 – 2026).

Infection with Helicobacter pylori (H. pylori) happens when the bacteria infect your stomach. This is most common in childhood. H. pylori infection, a prevalent cause of peptic ulcers, is thought to be present in more than half of the world's population. Because most individuals never become sick with H. pylori, they are unaware that they have it. Your doctor would most likely test you for H. pylori infection if you develop signs and symptoms of a peptic ulcer. Antibiotics can be used to treat an infection caused by H. pylori.

The market for helicobacter pylori diagnostics is growing due to rising Helicobacter pylori prevalence in emerging nations-

Helicobacter pylori is becoming less common in wealthy nations, whereas it is becoming more common in emerging economies. According to the Chinese University of Hong Kong (CUHK) Faculty of Medicine, about 4.4 billion individuals worldwide are infected with Helicobacter pylori in 2017. (H. pylori).

Furthermore, according to the same source, prevalence in Africa may reach up to 80%, which is the highest in the world, while in Asia, over 50% of the population is infected with H. pylori. Furthermore, according to the International Agency for Research on Cancer report 2014, about 952,000 new stomach cancer cases were reported globally in 2012, with around 734,000 gastric malignancies owing to H. pylori infection.

In order to improve the eradication of helicobacter pylori infection in Quebec, antibody-based detection tests are now accessible at a cheaper cost. Furthermore, the Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS), an independent authority reporting to Quebec's Minister of Health and Social Services, advises that the 13C-urea breath test be made available throughout the province. Due to the high incidence of Helicobacter pylori in Africa, the Helicobacter pylori diagnostics Market is predicted to grow at a fast rate. According to research published in the Gastroenterology Journal in 2017, Africa has the greatest frequency of H. pylori infection, at roughly 79 percent.

Diagnostic test restrictions are projected to be a key stumbling block to the Helicobacter pylori diagnostics market's growth. Serology-based tests, for example, have limited sensitivity and specificity since they can't tell the difference between current infection and IgG antibodies present after therapy.